Search
Madrigal Pharmaceuticals Inc
MDGLAdd to Watchlist
461.540USD
-31.570-6.40%
Market hours （ET）Quotes delayed by 15 min
10.63BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-30The current earnings forecast score of Madrigal Pharmaceuticals Inc is 8.12, ranking 168 out of 384 in the Biotechnology & Medical Research industry. The average price target is 557.00, with a high of 650.00 and a low of 456.00.
Analyst Rating
Based on
18
analysts
Buy
Current Rating
680.000
Target Price
+23.36%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Madrigal Pharmaceuticals Inc
MDGL
18
Beigene Ltd
ONC
28
Ionis Pharmaceuticals Inc
IONS
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Insmed Inc
INSM
23
1
2
3
...
99
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Madrigal Pharmaceuticals Inc's expected revenue for the next quarter?
Madrigal Pharmaceuticals Inc's expected revenue is 399.55M.
What is Madrigal Pharmaceuticals Inc's price target?
Analysts forecast that Madrigal Pharmaceuticals Inc's price target is USD 557.00, with the highest forecast at USD 650.00 and the lowest forecast at USD 456.00.
How have Madrigal Pharmaceuticals IncMDGL's recent earnings per share performed?
The market expectation was USD -1.99, while Madrigal Pharmaceuticals IncMDGL's earnings per share (EPS) for the previous quarter was USD -3.25. EPS for the next quarter is expected at USD -1.27.
What is the analyst rating for Madrigal Pharmaceuticals Inc?
Based on the ratings of Madrigal Pharmaceuticals Inc's stock from 18 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.